In addition to MGMT, other molecular biomarkers have been shown to separate GBM into prognostic groups.9 In this regard, expression of the proto-oncogene BCL-3, a nuclear factor-κB (NF-κB) co-regulator, was found to not only identify prognostic groups of GBM but also to potentially act as a predictor of response to alkylators like TMZ.10 This latter observation remains to be validated in a prospective study. The gene discussed is BCL3; the disease is glioblastoma.